Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.90 |
| ▸ | CNR2 | P34972 | 3/20 | 0.68 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193040 | 0.95 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL1228084 | 0.95 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL17467159 | 0.89 | CNR1 (0.72) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL14239652 | 0.87 | CNR1 (0.85) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL18120322 | 0.86 | CNR1 (0.69) | CNR1ALDH1A1CNR2FAAHTRPM8 | |
| SCHEMBL5032810 | 0.86 | CNR1 (0.79) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL12319236 | 0.85 | CNR1 (0.83) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL13767988 | 0.84 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL13518460 | 0.84 | CNR1 (0.82) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL1228841 | 0.84 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9668986-B2 | Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines | EPITECH GROUP S.R.L. (IT) | 2017-06-06 | — | — | US | disclosed |
| US-20150265551-A1 | OPHTHALMIC, INTRA-ARTICULAR OR INTRAVESICAL PREPARATIONS CONTAINING N-ACYL-ETHANOLAMINES | Epitech Group S.r.I. (IT) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265551-A1 | OPHTHALMIC, INTRA-ARTICULAR OR INTRAVESICAL PREPARATIONS CONTAINING N-ACYL-ETHANOLAMINES | UACA, AADAC, PHOSPHO1 | CNR1 316/4885ALDH1A1 916/4885CNR2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.